ANTIHYPERTENSIVE LABELING SHOULD INCLUDE DEMONSTRATED BENEFITS OF REDUCED STROKE INCIDENCE AND CORONARY EVENTS, FDA CARDIORENAL ADVISORY CMTE. AGREES